{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:27:03Z","timestamp":1789410423103,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Warsaw"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Prostate-specific membrane antigen (PSMA) is not only highly expressed on the surface prostate cancer cells but is also elevated during angiogenesis in other cancer cell types, including hepatocellular carcinoma (HCC). This study aimed to evaluate the feasibility of using PET\/CT imaging with [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 in HCC and its impact on patient management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifteen patients (13 men and two women; aged 55.6\u2009\u00b1\u200918.2\u00a0years) with HCC were enrolled in this prospective, single-institution study. All patients underwent contrast-enhanced MRI\/CT, [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT, and histopathological verification of lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No radiopharmaceutical-related adverse events were noted. Visual interpretation showed increased accumulation of [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 in all HCC patients. The tumor-to-liver ratio (TLR) was 3.6\u2009\u00b1\u20092.1, and the maximal standardized uptake value (SUV<jats:sub>max<\/jats:sub>) was 13.5\u2009\u00b1\u20097.1. There were no significant differences in the SUVs or TLR between newly diagnosed and recurrent patients. No statistically significant relationship was found between serum concentration of tumor markers (i.e., AFP, CA 19-9, CEA) and PET parameters. Results of the [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT changed the treatment strategy in five (33%) patients. PSMA staining showed visible heterogeneity in terms of intensity and distribution: the reaction was weak and only observed in a few vessels in pseudoglandular patterns of HCC, while it was homogeneously strong, with some hot spots, in trabecular patterns of HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT can detect PSMA expression in vivo in patients with HCC and is useful for guiding treatment strategies. Further investigation of the clinical utility of this method in HCC is warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-020-05017-0","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T21:09:39Z","timestamp":1599167379000},"page":"883-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["[68 Ga]Ga-Prostate-Specific Membrane Antigen PET\/CT: a novel method for imaging patients with hepatocellular carcinoma"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7434-6720","authenticated-orcid":false,"given":"Jolanta","family":"Kunikowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Cie\u015blak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Gierej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Patkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kotulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Zieniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kr\u00f3licki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"issue":"15","key":"5017_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. New England Journal of Medicine. 2019;380(15):1450\u201362. https:\/\/doi.org\/10.1056\/NEJMra1713263.","journal-title":"New England Journal of Medicine."},{"key":"5017_CR2","doi-asserted-by":"publisher","unstructured":"Tan CH, Low, S-CA, Thng CH. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J Hepatol. 2011;2011:519783-. doi:https:\/\/doi.org\/10.4061\/2011\/519783.","DOI":"10.4061\/2011\/519783"},{"issue":"4","key":"5017_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s12072-014-9566-0","volume":"8","author":"F Bertagna","year":"2014","unstructured":"Bertagna F, Bertoli M, Bosio G, Biasiotto G, Sadeghi R, Giubbini R, et al. Diagnostic role of radiolabelled choline PET or PET\/CT in hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology International. 2014;8(4):493\u2013500. https:\/\/doi.org\/10.1007\/s12072-014-9566-0.","journal-title":"Hepatology International."},{"issue":"5","key":"5017_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00259-018-3934-2","volume":"45","author":"J Kunikowska","year":"2018","unstructured":"Kunikowska J, Bartosz K, Leszek K. Glioblastoma multiforme: another potential application for 68Ga-PSMA PET\/CT as a guide for targeted therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2018;45(5):886\u20137. https:\/\/doi.org\/10.1007\/s00259-018-3934-2.","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging."},{"key":"5017_CR5","doi-asserted-by":"crossref","unstructured":"Kunikowska J, Kulinski R, Muylle K, Koziara H, Kr\u00f3licki L. 68Ga\u2013prostate-specific membrane antigen-11 PET\/CT: a new imaging option for recurrent glioblastoma multiforme? Clinical Nuclear Medicine. 2020;45(1).","DOI":"10.1097\/RLU.0000000000002806"},{"issue":"6","key":"5017_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2967\/jnumed.117.203570","volume":"59","author":"RA Salas Fragomeni","year":"2018","unstructured":"Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59(6):871\u20137. https:\/\/doi.org\/10.2967\/jnumed.117.203570.","journal-title":"J Nucl Med."},{"issue":"1","key":"5017_CR7","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical Cancer Research. 1997;3(1):81.","journal-title":"Clinical Cancer Research."},{"issue":"5","key":"5017_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2006.07.8097","volume":"25","author":"MI Milowsky","year":"2007","unstructured":"Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti\u2013prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. Journal of Clinical Oncology. 2007;25(5):540\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.07.8097.","journal-title":"Journal of Clinical Oncology."},{"issue":"5","key":"5017_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","volume":"46","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Seminars in Nuclear Medicine. 2016;46(5):405\u201318. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.04.004.","journal-title":"Seminars in Nuclear Medicine."},{"key":"5017_CR10","doi-asserted-by":"publisher","first-page":"1):1","DOI":"10.7150\/thno.37894","volume":"10","author":"RA Werner","year":"2020","unstructured":"Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, et al. (18)F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10:1):1\u201316. https:\/\/doi.org\/10.7150\/thno.37894.","journal-title":"Theranostics."},{"key":"5017_CR11","doi-asserted-by":"publisher","unstructured":"Jiao D, Li Y, Yang F, Han D, Wu J, Shi S, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin Transl Gastroenterol. 2019. https:\/\/doi.org\/10.14309\/ctg.0000000000000041.","DOI":"10.14309\/ctg.0000000000000041"},{"key":"5017_CR12","doi-asserted-by":"publisher","unstructured":"Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, et al. (68)Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. 2018. https:\/\/doi.org\/10.2967\/jnumed.118.214833.","DOI":"10.2967\/jnumed.118.214833"},{"issue":"9","key":"5017_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/RLU.0000000000002701","volume":"44","author":"S Kuyumcu","year":"2019","unstructured":"Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, et al. Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET\/CT. Clin Nucl Med. 2019;44(9):702\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000002701.","journal-title":"Clin Nucl Med."},{"issue":"1","key":"5017_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/ijnm.IJNM_145_19","volume":"35","author":"J Das","year":"2020","unstructured":"Das J, Ray S, Tapadia R, Midha D, Mallick I. Prostate-specific membrane antigen-expressing hepatic lesion: metastatic or hepatocellular carcinoma. Indian J Nucl Med. 2020;35(1):58\u201360. https:\/\/doi.org\/10.4103\/ijnm.IJNM_145_19.","journal-title":"Indian J Nucl Med."},{"key":"5017_CR15","doi-asserted-by":"crossref","unstructured":"Patel D, Loh H, Le K, Stevanovic A, Mansberg R. Incidental detection of hepatocellular carcinoma on 68Ga-labeled prostate-specific membrane antigen PET\/CT. Clinical Nuclear Medicine. 2017;42(11).","DOI":"10.1097\/RLU.0000000000001832"},{"key":"5017_CR16","doi-asserted-by":"crossref","unstructured":"Taneja S, Taneja R, Kashyap V, Jha A, Jena A. 68Ga-PSMA uptake in hepatocellular carcinoma. Clinical Nuclear Medicine. 2017;42(1).","DOI":"10.1097\/RLU.0000000000001355"},{"key":"5017_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15226\/2374-815X\/4\/2\/00180","volume":"4","author":"C Soydal","year":"2017","unstructured":"Soydal C, Alkan A, Ozkan E, Demirkaz\u0131k A, Kucuk N. Ga-68 PSMA accumulation in hepatocellular carcinoma. Journal of Gastroenterology, Pancreatology & Liver Disorders. 2017;4:1. https:\/\/doi.org\/10.15226\/2374-815X\/4\/2\/00180.","journal-title":"Journal of Gastroenterology, Pancreatology & Liver Disorders."},{"issue":"4","key":"5017_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00259-015-3297-x","volume":"43","author":"A Sasikumar","year":"2016","unstructured":"Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR. 68Ga-PSMA PET\/CT imaging in primary hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2016;43(4):795\u20136. https:\/\/doi.org\/10.1007\/s00259-015-3297-x.","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging."},{"issue":"41","key":"5017_CR19","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.18632\/oncotarget.27024","volume":"10","author":"Y Tolkach","year":"2019","unstructured":"Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. Oncotarget. 2019;10(41):4149\u201360. https:\/\/doi.org\/10.18632\/oncotarget.27024.","journal-title":"Oncotarget."},{"issue":"6","key":"5017_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"5017_CR21","doi-asserted-by":"publisher","unstructured":"Kratochwil C, Fendler W, Eiber M, Baum RP, Bozkurt M, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging. 2019;46. https:\/\/doi.org\/10.1007\/s00259-019-04485-3.","DOI":"10.1007\/s00259-019-04485-3"},{"issue":"9","key":"5017_CR22","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1007\/s00259-019-04636-6","volume":"47","author":"LM Mittlmeier","year":"2020","unstructured":"Mittlmeier LM, Unterrainer M, Todica A, Cyran CC, Rodler S, Bartenstein P, et al. PSMA PET\/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(9):2216\u20137. https:\/\/doi.org\/10.1007\/s00259-019-04636-6.","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging."},{"issue":"6","key":"5017_CR23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00259-020-04715-z","volume":"47","author":"J Kunikowska","year":"2020","unstructured":"Kunikowska J, Charzy\u0144ska I, Kuli\u0144ski R, Pawlak D, Maurin M, Kr\u00f3licki L. Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(6):1605\u20136. https:\/\/doi.org\/10.1007\/s00259-020-04715-z.","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05017-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05017-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05017-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:14:24Z","timestamp":1630707264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05017-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["5017"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05017-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"17 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the Ethical Committee of Medical University of Warsaw (KB\/2\/A\/2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors gave their written consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Calculations were performed on GraphPad PRISM 5 (GraphPad Software Inc.) and Excel for MAC (version 16.28, 2019 Microsoft).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}}]}}